A new face of endocannabinoids in pharmacotherapy part II. Role of endocannabinoids in inflammation-derived cardiovascular diseases

Journal of Physiology and Pharmacology

Volumn 65, Issue 2, 2014, Pages 183-191

  Zubrzycki, Marek ^a   Liebold, A ^a   Janecka, A ^b   Zubrzycka, M ^b  

^a UNIVERSITY OF ULM   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atherosclerosis; Cardiovascular system; Diabetic cardiomyopathy; Endocannabinoid system; Restenosis

Indexed keywords

1 (2, 4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1, 1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL) INDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ANANDAMIDE; APOLIPOPROTEIN E; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; DOXORUBICIN; ENDOCANNABINOID; FATTY ACID AMIDASE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; CELL DEATH; CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; ENDOTHELIUM CELL; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; LIVER CIRRHOSIS; MOLECULAR PATHOLOGY; NONHUMAN; PSYCHOPHARMACOTHERAPY; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; ANIMAL; CARDIOVASCULAR DISEASES; INFLAMMATION; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOCANNABINOIDS; HUMANS; INFLAMMATION;

EID: 84899623227     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
3. Malinowska B, Lupinski S, Godlewski G, Baranowska U, Schlicker E. Role of endocannabinoids in cardiovascular shock. J Physiol Pharmacol 2008; 59 (Suppl. 8): 91-107.
4. Glass CK, Witztum JL. Atherosclerosis, the road ahead. Cell 2001; 104: 503-516.
5. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
6. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischemia-reperfusion injury and preconditioning. Br J Pharmacol 2008; 153: 252-262.
7. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595-2600.
8. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-1672.
9. Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U. Energy balance regulation by endocannabinoids at central and peripheral levels. Trens Mol Med 2011; 17: 518-526.
10. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692-699.
11. Aronne LJ. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007; 120 (3 Suppl. 1): S26-S34.
12. Montecucco F, Matias I, Lenglet S, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205: 433-441.
13. Quercioli A, Pataky Z, Vincenti G, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32: 1369-1378.
14. Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
15. Maeda N, Osanai T, Kushibiki M, et al. Increased serum anandamide level at ruptured plaque site in patients with acute myocardial infarction. Fundam Clin Pharmacol 2009; 23: 351-357.
16. Lenglet S, Thomas A, Soehnlein O, et al. Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. Arterioscler Thromb Vasc Biol 2013; 33: 215-223.
17. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-1560.
18. O'Leary DH, Reuwer AQ, Nissen SE, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011; 97: 1143-1150.
19. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-786.
20. Hoyer FF, Steinmetz M, Zimmer S, et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 2011; 51: 1007-1014.
21. Mukhopadhyay P, Rajesh M, Pan H, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 2010; 48: 457-467.
22. Sachais BS. Platelet-endothelial interactions in atherosclerosis. Curr Atheroscler Rep 2001; 3: 412-416.
23. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 2008; 294: H1145-H1155.
24. Steffens S, Pacher P. Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol 2012; 167: 313-323.
25. Freeman-Anderson NE, Pickle TG, Netherland CD, Bales A, Buckley NE, Thewke DP. Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res 2008; 49: 2338-2346.
26. Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 174-179.
27. Zhao Y, Liu Y, Zhang W, et al. WIN55212-2 ameliorates atherosclerosis associated with suppression of proinflammatory responses in ApoE-knockout mice. Eur J Pharmacol 2010; 649: 285-292.
28. Zhao Y, Yuan Z, Liu Y, et al. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 2010; 55: 292-298.
29. Rajesh M, Mukhopadhyay P, Batkai S, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293: H2210-H2218.
30. Rajesh M, Pan H, Mukhopadhyay P, et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukocyte Biol 2007; 82: 1382-1389.
31. Liu J, Gao B, Mirshahi F, et al. Functional CB1 receptors in human vascular endothelial cells. Biochem J 2000; 345: 835-840.
32. Han KH, Lim S, Ryu J, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 2009; 84: 378-386.
33. Wheal AJ, Alexander SP, Randall MD. Hydrogen peroxide as a mediator of vasorelaxation evoked by Noleoylethanolamine and anandamide in rat small mesenteric arteries. Europ J Pharmacol 2012; 674: 384-390.
34. Dol-Gleizes F, Paumelle R, Visentin V, et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009; 29: 12-28.
35. Rajesh M, Mukhopadhyay P, Hasko G, Pacher P. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 2008; 377: 1248-1252.
36. Tiyerili V, Zimmer S, Jung S, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol 2010; 105: 465-477.
37. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-274.
38. Michel-Monigadon D, Steffens S, Molica F, Mach F, Montecucco F. Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology. Expert Rev Cardiovasc Ther 2012; 10: 1481-1486.
39. Montecucco F, Di Marzo V, da Silva RF, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-856.
40. Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm 2013; 2013: 659282.
41. Molica F, Matter CM, Burger F, et al. Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol 2012; 302: H1064-H1074.
42. Netherland CD, Pickle TG, Bales A, Thewke DP. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 2010; 213: 102-108.
43. Bojanowska E, Radziszewska E. Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid cb1 receptor act synergistically to reduce food intake and body weight in the rat. J Physiol Pharmacol 2011; 62: 395-402.
44. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 2008; 153: 290-298.
45. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease. therapeutic potential and limitations. Hypertension 2008; 52: 601-607.
46. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008.
47. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007; 100: 607-621.
48. Versaci F, Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 2004; 15: 307-311.
49. Lermann A. Restenosis: another "dysfunction" of endothelium. Circulation 2005; 111: 8-10.
50. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
51. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50: 193-211.
52. Molica F, Burger F, Thomas A, et al. Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. J Lipid Res 2013; 54: 1360-1368.
53. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011; 75: 1287-1296.
54. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
55. Korybalska K, Kawka E, Breborowicz A, Witowski J. Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury. J Physiol Pharmacol 2012; 63: 389-395.
56. Mukhopadhyay P, Batkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007; 50: 528-536.
57. Mukhopadhyay P, Rajesh M, Batkai S, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 2010; 85: 773-784.
58. Mukhopadhyay P, Horvath B, Rajesh M, et al. Fatty acid amide hydrolase is a key regulator of endocannabinoidinduced myocardial tissue injury. Free Radic Biol Med 2011; 50: 179-195.
59. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49: 330-352.
60. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57: 435-445.
61. Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktart N, Erkut MA. Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodkin's lymphoma. J Int Med Res 2005; 33: 687-692.
62. Lai R, Long Y, Li Q, Zhang X, Rong T. Oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity in rabbits. Exp Ther Med 2011; 2: 947-950.
63. Mukhopadhyay P, Rajesh M, Batkai S, et al. Role of superoxide, nitric oxide and peroxynitrite in doxorubicininduced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009; 296: H1466-H1483.
64. Garcia MI, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 1974; 23: 105-111.
65. Gwilt DJ, Petri M, Lewis PW, Nattrass M, Pentecost BL. Myocardial infarct size and mortality in diabetic patients. Br Heart J 1985; 54: 466-472.
66. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17 (Suppl. 1): S3-S8.
67. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-557.
68. Asghar O, Al-Sunni A, Khavandi K, et al. Diabetic cardiomyopathy. Clin Sci (Lond) 2009; 116: 741-760.
69. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11: 31-39.
70. Adameova A, Dhalla NS. Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 2014; 19: 25-33.
71. Aragno M, Mastrocola R, Medana C, et al. Oxidative stressdependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 2006; 147: 5967-5974.
72. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
73. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070.
74. Falco-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012; 17: 325-344.
75. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
76. Mariappan N, Elks CM, Sriramula S, et al. NF-kappaBinduced oxidative stress contributes to mitochondrial and cardiacv dysfunction in type II diabetes. Cardiovasc Res 2010; 85: 473-483.
77. Lorenzo O, Picatoste B, Ares-Carrasco S, Ramirez E, Egido J, Tunon J. Potential role of nuclear factor kB in diabetic cardiomyopathy. Mediators Inflamm 2011; 2011: 652097.
78. Stratmann B, Tschoepe D. The diabetic heart: sweet, fatty and stressed. Exper Rev Cardiovasc Ther 2011; 9: 1093-1096.
79. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002; 51: 514-521.
80. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010; 56: 2115-2125.
81. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetesinduced myocardial structural changes. Circ Res 2003; 92: 785-792.
82. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51.
83. Dillmann WH. Diabetes and thyroid hormone-induced changes in cardiac function and their molecular basis. Annu Rev Med 1989; 40: 373-394.
84. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998; 40: 239-247.
85. Adeghate E, Kalasz H, Veress G, Teke K. Medicinal chemistry of drugs used in diabetic cardiomyopathy. Curr Med Chem 2010; 17: 517-551.
86. Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes 2006; 30 (Suppl. 1): S7-S12.
87. Annuzzi G, Piscitelli F, Di Marino L, et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 2010; 9: 43.
88. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565: 207-211.
89. Vilches-Flores A, Delgado-Buenrostro NL, Navarrete-Vazquez G, Villalobos-Molina R. CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets. Regul Pept 2010; 163: 81-87.
90. Rajesh M, Mukhopadhyay P, Hasko G, Liaudet L, Mackie K, Pacher P. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and-independent mitogenactivated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol 2010; 160: 688-700.
91. Rajesh M, Batkai S, Kechrid M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012; 61: 716-727.
92. Barutta F, Corbelli A, Mastrocola R, et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010; 59: 1046-1054.
93. El-Remessy AB, Rajesh M, Mukhopadhyay P, et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia 2011; 54: 1567-1578.
94. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 2009; 31: 63-77.
95. Horvath B, Mukhopadhyay P, Hasko G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 2012; 180: 432-442.
96. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007; 293: H610-H619.
97. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-527.
98. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
99. Stanley CP, Hind WH, O'Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol 2013; 75: 313-322.
100. El-Remessy AB, Khalifa S, Ola S, Ibrahim AS, Liou GI. Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes. Mol Vis 2010; 16: 1487-1495.
101. Bolognini D, Costa B, Maione S, et al. The plant cannabinoid delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 2010; 160: 677-687.
102. Batkai S, Mukhopadhyay P, Horvath B, e t al. Delta(8)-tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response involving CB(2) receptors. Br J Pharmacol 2012; 165: 2450-2461.
103. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44: 994-1002.
104. Theocharidou E, Krag A, Bendtsen F, Moller S, Burroughs AK. Cardiac dysfunction in cirrhosis-does adrenal function play a role? A hypothesis. Liver Int 2012; 32: 1327-1332.
105. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005; 146: 315-323.
106. Batkai S, Rajesh M, Mukhopadhyay P, et al. Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol 2007; 293: H909-H918.
107. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-676.
108. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832.
109. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755.
110. Batkai S, Osei-Hyiaman D, Pan H, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007; 21: 1788-1800.
111. Cao Z, Mulvihill MM, Mukhopadhyay P, et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013; 144: 808-817.